If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Baqsimi™ (glucagon) nasal powder
3mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
BAQSIMI™ (glucagon) nasal powder: Use in Pediatric Patients Under the Age of 4 Years
Baqsimi (glucagon nasal powder) is not indicated for the treatment of severe hypoglycemia in pediatric patients under the age of 4 years.
Baqsimi is not indicated for the treatment of severe hypoglycemia in pediatric patients under the age of 4 years. The safety and effectiveness of Baqsimi have not been established in pediatric patients younger than 4 years of age.1
Baqsimi is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in patients with diabetes ages 4 and above.1
The safety and effectiveness of Baqsimi for the treatment of severe hypoglycemia in patients with diabetes have been established in pediatric patients ages 4 years and above. Use of Baqsimi for this indication is supported by evidence from a study in 48 pediatric patients from 4 to <17 years of age with T1DM.1
Enclosed Prescribing Information
BAQSIMI™ (glucagon) nasal powder, for intranasal use, Lilly
1. Baqsimi [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
Glossary
Baqsimi = Baqsimi™ (glucagon) nasal powder
T1DM = type 1 diabetes mellitus
Date of Last Review: August 15, 2019
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 8pm ET
